mergers & acquisitions

Among Flatiron's assets is a database developed in collaboration with Foundation Medicine intended to help biopharma firms develop more effective cancer therapies.

Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.

The firm's CEO said he's seeing significant growth in research applications from its RNA in-situ hybridization technology, and sees potential for its use in clinical settings.

Ireland-based Luxcel is a developer of real-time fluorescence plate reader-based in vitro cell assay kits.

Radiant has built large-scale libraries of genetic diversity using a platform that combines sequencing, bioinformatics, synthetic biology, and other technologies.

Maravai was launched in 2014 by private equity firm GTCR in partnership with two former Gen-Probe executives.

GenScript believes that CustomArray's oligonucleotide synthesis and microarray manufacturing technology will enable it to better serve its customers.

There were fewer mergers and acquisitions in the omics space in 2017, breaking a two-year streak of growth — however, the deals themselves stayed fairly large.

Genoptix has also agreed to provide a $1.8 million secured bridge loan facility to fund Rosetta’s operations through the closing of the deal.

FactBio's primary offering is its Knowledge Sharing Platform, which includes tools for data discovery and curation.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.